Case Study: Rinvoq’s brand Dermatology market expansion strategy
Rinvoq is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Rinvoq is the brand of... Read More
Case Study: USFDA approval of AbbVie’s RINVOQ (upadacitinib)
U.S. Food and Drug Administration (FDA) has approved RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment... Read More